Fennec Pharmaceuticals Inc. (FENC)

Fennec Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Net Income	-9.74	-0.44	-16.05
Stock-Based Compensation	7.03	5.06	5.35
Other Adjustments	5.07	5.41	0.33
Change in Receivables	-12.44	-7.87	-7.27
Changes in Inventories	-1.28	0.58	-1.58
Changes in Accounts Payable	1.39	-0.54	1.39
Changes in Accrued Expenses	2.21	-0.33	0.58
Changes in Unearned Revenue	-	24.81	-
Changes in Other Operating Activities	-4.72	0.29	0.11
Operating Cash Flow	-12.47	26.98	-17.14
Long-Term Debt Repaid	-19.48	-13	5
Net Long-Term Debt Issued (Repaid)	-19.48	-13	5
Issuance of Common Stock	44.24	1.3	1.72
Net Common Stock Issued (Repurchased)	44.24	1.3	1.72
Other Financing Activities	-2.14	-1.92	-0.08
Financing Cash Flow	22.63	-13.62	6.64
Net Cash Flow	10.15	13.37	-10.51
Free Cash Flow	-12.47	26.98	-17.14
FCF Margin	-27.94%	56.75%	-80.67%
Free Cash Flow Per Share	-0.44	0.99	-0.65
Levered Free Cash Flow	-31.61	11.38	-10.56
Unlevered Free Cash Flow	-8.74	40.59	-12.28

Updated Mar 24, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q